nivolumab / OS Cancer Research Results

NIV, nivolumab: Click to Expand ⟱
Features: Immunomodulatory antibodies
Two different inhibitory pathways that block antitumor T cell responses.


OS, overall survival: Click to Expand ⟱
Source:
Type:
Overall survival
Scientific Papers found: Click to Expand⟱
7706- lpi,  NIV,    Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
- Trial, Melanoma, NA
OS↑,
5804- MET,  NIV,    Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up.
- Case Report, PC, NA
OS↑, Dose↝,
7707- NIV,  lpi,    Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial
- Trial, RCC, NA
OS↑, Dose↝,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 2,  

Functional Outcomes(tgid=23) ⓘ

OS↑, 3,  
Total Targets: 2

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: OS, overall survival
3 nivolumab
2 ipilimumab
1 Metformin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:22  Target#:229  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page